Latest news with #PrivateSector
Yahoo
10 minutes ago
- Business
- Yahoo
Poly Medicure Ltd (BOM:531768) Q1 2026 Earnings Call Highlights: Strategic Expansion and ...
Release Date: August 08, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Poly Medicure Ltd (BOM:531768) was awarded Medical Device Provider of the Year 2025, highlighting its strong reputation in the healthcare sector. The company has signed two new contract manufacturing agreements, expanding its presence in the US and Hong Kong markets. Poly Medicure Ltd has established a wholly-owned subsidiary in Brazil, indicating a strategic move to expand its market presence in South America. The company's domestic revenue grew by 20% in Q1, with a significant increase in the private sector, reflecting a strong focus on sustainable domestic business. The company is investing in R&D, with a 20% increase in spending, to develop high-end technology segments such as cardiology and critical care. Negative Points International revenue saw a slight dip of 1% due to growth challenges in the European market and geopolitical uncertainties. The company faces challenges from tariffs imposed by the US, which could impact export markets. There is a slowdown in the infusion therapy business, primarily due to challenges in the European market. The company has lowered its international revenue growth guidance to 5-10% from the earlier 12-15%, reflecting current market uncertainties. The competitive intensity from Chinese companies in Europe has increased, affecting pricing and market dynamics. Q & A Highlights Warning! GuruFocus has detected 2 Warning Signs with BOM:531768. Q: Despite a lower international business, the gross margin was high during the quarter. What drove this margin, and what is sustainable for the full year? A: The gross margin historically tracks between 65% and 67%. As we delve deeper into critical cardiology areas, the product prices are higher, leading to higher gross margins. A run rate between 65% to 68% is sustainable. (Unidentified_3, Managing Director) Q: Can you explain the growth challenges in Europe and the expected easing in subsequent quarters? A: Europe faced financial restructuring and liquidity issues, leading to reduced inventory levels. However, demand is returning as inventory levels normalize, and we expect 5% to 10% growth in international business in the coming quarters. (Unidentified_3, Managing Director) Q: What are Poly Medicure's expansion plans for the HDF and CRRT portfolios in the renal segment? A: We plan to launch our first HDF machine in 2026, which is currently under development. CRRT is not a focus right now but may be considered for future development. (Unidentified_3, Managing Director) Q: Could you provide details on the contract manufacturing contracts in vascular and pain management? A: These are CDMO opportunities with innovative, patented devices. Revenue should start coming in from the next financial year, but it will take 2-3 years to scale up significantly. (Unidentified_3, Managing Director) Q: How is the company planning to address the competitive intensity from Chinese companies in Europe? A: The competitive intensity from Chinese companies has decreased, and we are seeing demand bounce back in Europe. We are confident that Europe will perform better in the current quarter. (Unidentified_3, Managing Director) For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Sign in to access your portfolio
Bloomberg
2 days ago
- Business
- Bloomberg
White House Crypto Adviser Bo Hines to Return to Private Sector
Bo Hines, the head of the White House Presidential Council of Advisers for Digital Assets, said he was stepping down and returning to the private sector. Hines called his role 'the honor of a lifetime' in a post on X. 'Together, we have positioned America as the crypto capital of the world. I'm deeply grateful to the industry for its unwavering support — I love this community and all we've built together.'
Zawya
3 days ago
- Business
- Zawya
Saudi credit growth slows in June; consumer spending increases: Report
Riyadh: Credit growth slowed month-on-month (MoM) in June 2025 across Saudi banks, attributed to weak mortgage origination (flat Year-on-year (YoY) and -28% MoM), according to the recent Saudi Banking Monthly Report by Al Rajhi Capital Research. Corporate loans maintained a solid trajectory in June, with growth remaining supportive for the second consecutive month, led by the private sector, pushing the unadjusted LDR down by 54 basis points (bps) on a monthly basis. On the other hand, consumer spending soared by almost 9% in June, which was reassuring amid concerns of a slowdown in the Saudi economy. Banks' profitability in June was solid, which was also confirmed by their second-quarter (Q2) 2025 earnings. Al Rajhi Capital Research concluded: 'Guidance from banks that conducted calls so far showed some pessimism on NIMs, but remained confident about asset quality.'
Forbes
5 days ago
- Business
- Forbes
Oregon's Tax Relief For Housing Affordability Too Complicated
Property tax abatements, reductions in tax rates or collections, in exchange for affordable housing, and tax exemptions, elimination of tax obligations in exchange for affordable housing are relatively common across the country and take different forms. Previous posts have looked at the different approaches and looked an abatement program in Montgomery, County, Maryland. Both abatement and exemption programs can have a variety of goals or agendas. Oregon's Vertical Housing Development Zone (VHDZ) is a rather ambitious program that intends not just to create affordable housing but to promote density and height, both of which are arguably related to affordability. The program is complex, and complexity can contribute to costs and lack of participation. Here's a look at the VHDZ. The VHDZ program is authorized by state law, and administered by local cities and counties. The City of Milwaukie, Oregon describes its program as 'designed to encourage the private sector to build higher-density mixed-use development (first floor commercial with residential above) and affordable housing in Milwaukie. The tool provides a partial tax exemption on increased property value for qualified projects and a land exemption if affordable housing is developed.' A project qualifies for the program if it is in an area designated as a development zone, has to be a multiple-story building, with half of the ground floor fronting a 'primary public street,' and half of that used for non-residential use. The state law has a test based on entry ways and amenities on the ground floor. Projects that meet these requirements can receive a 10-year property tax exemption based on 20% of the value of the first four residential floors above the ground floor up to 80% of the total value of new construction. An additional exemption is available if some or all of the floors have affordable housing that rents for no more than 80% of the local Area Median Income (AMI). Has anyone used the program? I couldn't find any projects in the public realm that cite the program. The Axletree Apartments, completed in 2019, touts 110 apartments with five-stories. According to the developer's website, 'It's notable for being the first newly-constructed multi-family development in Downtown Milwaukie in over a decade.' But there's no indication that there are affordable units in the building, however, or that it availed itself of the VHDZ even though it is in the zone. And an extensive report on Milwaukie's Housing Production Strategy (HPS), doesn't refer to the program at all even while citing other programs like the Multiple-Unit Limited Tax Exemption Program (MUPTE). Just because I didn't find any examples doesn't mean there aren't any in Milwaukie, but it is peculiar considering the availability as a tool to motivate more dense construction. A legislative review of multiple programs including the VHDZ found that 'it does not provide upfront financing, which may limit its effectiveness at increasing the supply of workforce rental housing.' The report also notes that the 'partial exemption could be relatively ineffective at certain times because it has been implemented as a partial [real market value] exemption. Real Market Value in Oregon is the assessor's estimate of what the property would sell for on the open market as of January 1 of the tax year. The report also concludes that 'in terms of efficiency, the VHDZ partial exemption may be relatively difficult for cities or counties to administer given the requirements for zone designation and the unique exemption amount formula.' An analysis by the National Multifamily Housing Council (NMHC) quite sensibly concluded that, 'administering policies with greater complexity and difficulty requires more time and resources. An onerous process also discourages developers from participating in a program and developing units.' And it can also discourage cities from using them as well. Complex and locked in formulas for abatement and exemption programs for affordable housing can limit their effectiveness. Next, all the factors considered, what are the ideal elements for tax abatement or exemption program to efficiently and reliably incentivize the creation of affordable housing?
Iraqi News
30-07-2025
- Business
- Iraqi News
Iraq's pharmaceutical industry flourishes, saving over $1 billion annually
Baghdad ( – Iraq is witnessing significant advancements in localizing its pharmaceutical industry, a strategic move that has already saved the country over $1 billion annually. Hamoudi Al-Lami, Advisor to the Prime Minister for Industry and Private Sector Development, announced today, Tuesday (July 29, 2025), that 34 pharmaceutical factories are currently operating at full capacity, with an additional 178 applications pending for new drug manufacturing plants. Al-Lami told the Iraqi News Agency (INA) that the government initiated a comprehensive program to localize the pharmaceutical industry from its very first week in office. This drive is underpinned by supportive Council of Ministers resolutions issued in 2023, which facilitate both the expansion of existing projects and the establishment of new ones. These facilitations include offering loans to investors and accepting production lines as collateral for opening credit. Government support extends to ensuring the availability of essential raw materials for both current and future industrial projects. Furthermore, the Ministry of Health has significantly reviewed and increased the prices at which it purchases medicines from national factories, more than doubling them. This policy has led to a surge in the value of contracts for the General Company for Marketing Drugs, rising from 144 billion Iraqi Dinars at the start of the current government's term to over 600 billion Dinars today. Al-Lami highlighted that domestically produced medicines now cover approximately a quarter of the cost of imported drugs, directly contributing to the annual savings exceeding $1 billion. The number of applications to establish factories for medicines and medical supplies has climbed to 178 as of July 1, up from 100 previously. These applications cover a diverse range of products, including various medicines, medical consumables, surgical sutures, intravenous solutions, syringes, and other medical devices, all thanks to the robust government support for investors. The number of operational pharmaceutical factories in Iraq has increased to 34, a notable rise from 22 at the time the current government was formed. Al-Lami pointed out that the 22 factories had remained constant since the establishment of the first pharmaceutical factory in 1956 until the current administration. The newly established factories are now operating at full capacity, substantially increasing the coverage of locally produced medicines. Al-Lami stressed that domestically produced medicines adhere to the highest international standards and specifications, undergoing rigorous pharmaceutical oversight using the latest technologies. Clinical trials are also being conducted for complex medications, such as those for blood diseases and cancer, which are now being produced locally through technology transfer from international companies. Concluding his remarks, Al-Lami reiterated that the Prime Minister's directives emphasize that 'efficacy and safety in drug production are a red line.' He highlighted that during the current government's tenure, 38 new medications for hypertension, 33 for diabetes, and 58 types of antibiotics covering both adults and children in various forms have been added to local production. Furthermore, the local production of 25 cancer treatment drugs has commenced through technology transfer initiatives.
